Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test
FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/11/12/1901 |
| _version_ | 1827661475048587264 |
|---|---|
| author | Damien Vasseur Hela Sassi Arnaud Bayle Marco Tagliamento Benjamin Besse Christophe Marzac Ahmadreza Arbab Nathalie Auger Sophie Cotteret Mihaela Aldea Félix Blanc-Durand Arthur Géraud Anas Gazzah Yohann Loriot Antoine Hollebecque Patricia Martín-Romano Maud Ngo-Camus Claudio Nicotra Santiago Ponce Madona Sakkal Olivier Caron Cristina Smolenschi Jean-Baptiste Micol Antoine Italiano Etienne Rouleau Ludovic Lacroix |
| author_facet | Damien Vasseur Hela Sassi Arnaud Bayle Marco Tagliamento Benjamin Besse Christophe Marzac Ahmadreza Arbab Nathalie Auger Sophie Cotteret Mihaela Aldea Félix Blanc-Durand Arthur Géraud Anas Gazzah Yohann Loriot Antoine Hollebecque Patricia Martín-Romano Maud Ngo-Camus Claudio Nicotra Santiago Ponce Madona Sakkal Olivier Caron Cristina Smolenschi Jean-Baptiste Micol Antoine Italiano Etienne Rouleau Ludovic Lacroix |
| author_sort | Damien Vasseur |
| collection | DOAJ |
| description | FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels’ size raise new questions in terms of detection of incidental germline alterations, occult malignancies and clonal hematopoiesis of indeterminate potential mutations. In this review, after a technological discussion and description of the common problematics encountered, we establish recommendations in properly using these FDA-approved tests in a molecular-tumor-board context. |
| first_indexed | 2024-03-10T00:09:54Z |
| format | Article |
| id | doaj.art-2e99673fed1041c0a965376c66400eb2 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T00:09:54Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-2e99673fed1041c0a965376c66400eb22023-11-23T16:01:12ZengMDPI AGCells2073-44092022-06-011112190110.3390/cells11121901Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved TestDamien Vasseur0Hela Sassi1Arnaud Bayle2Marco Tagliamento3Benjamin Besse4Christophe Marzac5Ahmadreza Arbab6Nathalie Auger7Sophie Cotteret8Mihaela Aldea9Félix Blanc-Durand10Arthur Géraud11Anas Gazzah12Yohann Loriot13Antoine Hollebecque14Patricia Martín-Romano15Maud Ngo-Camus16Claudio Nicotra17Santiago Ponce18Madona Sakkal19Olivier Caron20Cristina Smolenschi21Jean-Baptiste Micol22Antoine Italiano23Etienne Rouleau24Ludovic Lacroix25Medical Biology and Pathology Department, Gustave Roussy, F-94805 Villejuif, FranceMedical Biology and Pathology Department, Gustave Roussy, F-94805 Villejuif, FranceDrug Development Department (DITEP), Gustave Roussy, F-94805 Villejuif, FranceMedical Oncology Department, Gustave Roussy, F-94805 Villejuif, FranceMedical Oncology Department, Gustave Roussy, F-94805 Villejuif, FranceMedical Biology and Pathology Department, Gustave Roussy, F-94805 Villejuif, FranceMedical Biology and Pathology Department, Gustave Roussy, F-94805 Villejuif, FranceMedical Biology and Pathology Department, Gustave Roussy, F-94805 Villejuif, FranceMedical Biology and Pathology Department, Gustave Roussy, F-94805 Villejuif, FranceMedical Oncology Department, Gustave Roussy, F-94805 Villejuif, FranceGynecological Cancer Unit, Department of Medicine, Gustave Roussy, F-94805 Villejuif, FranceDrug Development Department (DITEP), Gustave Roussy, F-94805 Villejuif, FranceMedical Oncology Department, Gustave Roussy, F-94805 Villejuif, FranceMedical Oncology Department, Gustave Roussy, F-94805 Villejuif, FranceMedical Oncology Department, Gustave Roussy, F-94805 Villejuif, FranceDrug Development Department (DITEP), Gustave Roussy, F-94805 Villejuif, FranceDrug Development Department (DITEP), Gustave Roussy, F-94805 Villejuif, FranceDrug Development Department (DITEP), Gustave Roussy, F-94805 Villejuif, FranceDrug Development Department (DITEP), Gustave Roussy, F-94805 Villejuif, FranceDermatology Unit, Oncology Department, Gustave Roussy, F-94805 Villejuif, FranceMedical Oncology Department, Gustave Roussy, F-94805 Villejuif, FranceDermatology Unit, Oncology Department, Gustave Roussy, F-94805 Villejuif, FranceDepartment of Hematology, Gustave Roussy, F-94805 Villejuif, FranceDrug Development Department (DITEP), Gustave Roussy, F-94805 Villejuif, FranceMedical Biology and Pathology Department, Gustave Roussy, F-94805 Villejuif, FranceMedical Biology and Pathology Department, Gustave Roussy, F-94805 Villejuif, FranceFDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels’ size raise new questions in terms of detection of incidental germline alterations, occult malignancies and clonal hematopoiesis of indeterminate potential mutations. In this review, after a technological discussion and description of the common problematics encountered, we establish recommendations in properly using these FDA-approved tests in a molecular-tumor-board context.https://www.mdpi.com/2073-4409/11/12/1901cfDNAliquid biopsynext-generation sequencingmolecular tumor boardFDA-approved |
| spellingShingle | Damien Vasseur Hela Sassi Arnaud Bayle Marco Tagliamento Benjamin Besse Christophe Marzac Ahmadreza Arbab Nathalie Auger Sophie Cotteret Mihaela Aldea Félix Blanc-Durand Arthur Géraud Anas Gazzah Yohann Loriot Antoine Hollebecque Patricia Martín-Romano Maud Ngo-Camus Claudio Nicotra Santiago Ponce Madona Sakkal Olivier Caron Cristina Smolenschi Jean-Baptiste Micol Antoine Italiano Etienne Rouleau Ludovic Lacroix Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test Cells cfDNA liquid biopsy next-generation sequencing molecular tumor board FDA-approved |
| title | Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test |
| title_full | Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test |
| title_fullStr | Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test |
| title_full_unstemmed | Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test |
| title_short | Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test |
| title_sort | next generation sequencing on circulating tumor dna in advanced solid cancer swiss army knife for the molecular tumor board a review of the literature focused on fda approved test |
| topic | cfDNA liquid biopsy next-generation sequencing molecular tumor board FDA-approved |
| url | https://www.mdpi.com/2073-4409/11/12/1901 |
| work_keys_str_mv | AT damienvasseur nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT helasassi nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT arnaudbayle nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT marcotagliamento nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT benjaminbesse nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT christophemarzac nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT ahmadrezaarbab nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT nathalieauger nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT sophiecotteret nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT mihaelaaldea nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT felixblancdurand nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT arthurgeraud nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT anasgazzah nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT yohannloriot nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT antoinehollebecque nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT patriciamartinromano nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT maudngocamus nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT claudionicotra nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT santiagoponce nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT madonasakkal nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT oliviercaron nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT cristinasmolenschi nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT jeanbaptistemicol nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT antoineitaliano nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT etiennerouleau nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest AT ludoviclacroix nextgenerationsequencingoncirculatingtumordnainadvancedsolidcancerswissarmyknifeforthemoleculartumorboardareviewoftheliteraturefocusedonfdaapprovedtest |